[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,113,223
  • Shares Outstanding, K 158,676
  • Annual Sales, $ 0 K
  • Annual Income, $ -512,540 K
  • EBIT $ -555 M
  • EBITDA $ -554 M
  • 60-Month Beta 0.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.85

Options Overview Details

View History
  • Implied Volatility 67.84% (-6.55%)
  • Historical Volatility 60.27%
  • IV Percentile 11%
  • IV Rank 13.26%
  • IV High 155.38% on 11/13/25
  • IV Low 54.46% on 08/18/25
  • Expected Move (DTE 4) 1.45 (7.36%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 638
  • Volume Avg (30-Day) 292
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 9,756
  • Open Int (30-Day) 9,970
  • Expected Range 18.18 to 21.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.62
  • Number of Estimates 10
  • High Estimate $0.32
  • Low Estimate $-0.79
  • Prior Year $-0.72
  • Growth Rate Est. (year over year) +13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.10 +8.40%
on 05/04/26
21.80 -10.00%
on 04/16/26
unch (unch)
since 04/08/26
3-Month
17.86 +9.85%
on 03/30/26
23.46 -16.37%
on 03/25/26
-1.46 (-6.93%)
since 02/06/26
52-Week
12.58 +55.96%
on 09/22/25
23.77 -17.46%
on 02/03/26
+5.19 (+35.97%)
since 05/08/25

Most Recent Stories

More News
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

FDA approved AVLAYAHâ„¢ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrier AVLAYAH launched in U.S....

DNLI : 19.62 (-0.46%)
Denali's First Commercial Quarter Will Show Whether Hunter Syndrome Launch Mechanics Actually Work

Barchart Research What to Expect from DNLI Earnings DNLI Generated May 4, 2026 Current Price $18.67 EPS Estimate $$-0.73 Consensus Rating Strong Buy Average Move 5.31% Denali's First Commercial Quarter...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicleâ„¢ technology Results from ongoing Phase 1/2 study in patients with...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAHâ„¢ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAHâ„¢ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Presents Enzyme TransportVehicleâ„¢ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposiumâ„¢

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrum Launch readiness established...

DNLI : 19.62 (-0.46%)
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicleâ„¢ Programs at the 2026 WORLDSymposiumâ„¢

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicleâ„¢...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicleâ„¢ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposiumâ„¢

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase...

DNLI : 19.62 (-0.46%)
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter syndrome Expecting multiple clinical data readouts...

DNLI : 19.62 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 21.38
2nd Resistance Point 20.95
1st Resistance Point 20.29
Last Price 19.62
1st Support Level 19.20
2nd Support Level 18.77
3rd Support Level 18.11

See More

52-Week High 23.77
Last Price 19.62
Fibonacci 61.8% 19.50
Fibonacci 50% 18.17
Fibonacci 38.2% 16.85
52-Week Low 12.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.